Gore & Associates announced FDA approval of the Gore Viabahn Fortegra venous stent—previously known as the Gore Viafor ...

W.L. Gore & Associates announced today that the FDA approved its Viabahn Fortegra venous stent, formerly known as Viafort.

FDA approves first venous stent for IVC and iliofemoral veins, offering a new treatment for deep venous disease with proven 12-month patency.

W. L. Gore & Associates has secured FDA approval for the GORE VIABAHN FORTEGRA Venous Stent — previously known as the GORE ...

May-Thurner syndrome, also known as iliac vein compression syndrome or Cockett's syndrome, affects two blood vessels that go to your legs. It could make you more likely to have a DVT (deep vein ...

LAS VEGAS, NV—A self-expanding nitinol stent is effective for the treatment of venous obstructions in the iliac and femoral veins, according to 12-month data from the nonrandomized, multicenter ...

Although the formation of collaterals is classically regarded as a compensatory mechanism to bypass and thus alleviate an obstruction, the mechanism and inducement of collateral formation are unknown.

Abre (Medtronic), a dedicated venous stent, has a 12-month primary patency rate of 88%, exceeding the performance goal for effectiveness in its pivotal investigational device exemption (IDE) trial.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Rates of patency and freedom from target ...

The major obstacle for precise selection of patients for venous outflow stenting is the lack of a reliable test to measure a hemodynamically significant stenosis. The key for the physician is to be ...